Stephen P. Robertson, Chief Legal Officer of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), filed a Form 4 on September 11, 2026, disclosing the automatic sale of 11,939 shares of common stock on September 10, 2026, to cover tax withholding obligations tied to vesting Performance Stock Units.

Key Highlights

  • Reporting person: Stephen P. Robertson, Chief Legal Officer of Aurinia Pharmaceuticals Inc.
  • Transaction date: September 10, 2026, involving 11,939 shares disposed of (transaction code S).
  • Weighted average price: $15.95 per share, with individual transactions ranging from $15.95 to $15.96, inclusive.
  • Purpose of sale: Shares were automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award.
  • Beneficial ownership following transaction: 588,848 shares of common stock held directly.

Robertson PSU Vesting Triggers Automatic Tax-Related Sale at Aurinia Pharmaceuticals

According to the filing, Stephen P. Robertson, serving as Chief Legal Officer of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), disposed of 11,939 shares of common stock on September 10, 2026. The filing states that these shares were "automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award."

The filing discloses that the reported price of $15.95 per share is a weighted average, with the shares sold across multiple transactions at prices ranging from $15.95 to $15.96, inclusive. Robertson has undertaken to provide full information regarding the number of shares sold at each separate price within that range upon request by the issuer, any security holder, or SEC staff, according to the filing.

Following the reported transaction, Robertson's directly held beneficial ownership of Aurinia Pharmaceuticals common stock stands at 588,848 shares, as reported in the filing. The Form 4 was signed by Robertson and filed on September 11, 2026, one day after the transaction date.

What Was Disclosed

The filing reports a single disposition of 11,939 common shares by Aurinia Pharmaceuticals' Chief Legal Officer at a weighted average price of $15.95, carried out automatically to satisfy tax withholding upon PSU vesting, leaving him with 588,848 directly held shares.